Hit discovery for trained immunity and tolerance
Van derden14/12/20
Hit discovery against epigenetic targets
Do you want to learn about:
- Trained immunity.
- The role of epigenetic targets in trained immunity.
- Hit discovery through ultra-High throughput screening of large libraries.
- Industry standard Hit-to-Lead (H2L) biological profiling frameworks.
Join us for this webinar in which we will focus on epigenetic targets:
• Center for Open Innovation in LEad Discovery (COILED) is a collaborative drug discovery program focused on epigenetic targets.
• Modulation of trained innate immunity for treatment of hyper-inflammation and immune deficiency-driven diseases like sepsis and cancer.
• ultra-High Throughput Screening (uHTS) campaign of 300,000 diverse set of compounds has led to the identification of 3 novel scaffolds (starting points) that progressed into Hit-to-Lead (H2L) phase.
Dr. Saman Honarnejad – Director Drug Discovery at Pivot Park Screening CentreDuration
Presentation: 45 minutes
You can view this webinar from your computer, tablet or mobile phone.
About the presenter:
Dr. Saman Honarnejad is a biotechnologist with over a decade of experience in High Throughput Biology. At Pivot Park Screening Centre (PPSC) in Oss, the Netherlands, he is involved in cellular and biochemical assay development, ultra-High Throughput screening (uHTS) and Hit-to-Lead (H2L) biological compound profiling within a wide range of commercial, academic and public-private partnership projects including the European Lead Factory (ELF).
Prior to joining PPSC in 2017, he was active in high-content compound profiling method development at Max-Planck Institute (Germany), Harvard Medical School (United States) and Heidelberg University (Germany) and further optimized microarray-based cDNA/RNAi functional screening assays at the European Molecular Biology Laboratory (EMBL).
